Official press releases and corporate announcements from Synbio International, Inc. (OTC: SYIN)
Synbio launches Healing Force™ Anxiety Relief, a natural stress-and-anxiety wellness product, marking the company's transition from a pre-revenue shell into an operating business with a direct-to-consumer sales channel.
Read MoreThe company secures Deposit/Withdrawal at Custodian and Direct Registration System processing through Pacific Stock Transfer Company, modernizing its trading infrastructure and easing electronic share transfers for shareholders.
Read MoreSynbio executes a Master Services Agreement with CRO Services Pty Ltd, an Australian clinical research organization, to begin a proof-of-concept trial evaluating FacialDx's NIMS™ technology for PTSD and depression screening.
Read MorePsychiatrist and clinical research veteran Dr. Nick Vatakis, MD joins as Medical Director and board member, and will oversee the feasibility trial for Synbio's AI-driven facial analysis depression screening software.
Read MoreSynbio expands its FacialDx partnership with a staged $200,000 share purchase, an option to convert up to $2.5 million in future trial costs into equity, and a new Joint Trial Oversight Committee.
Read MoreVeteran CPA Desiree Cain joins as Chief Financial Officer and board member to lead financial operations, SEC and OTC Markets reporting, and corporate governance.
Read MoreSynbio enters a Clinical Trial License Agreement with FacialDx Inc. to validate NIMS™, an AI-powered facial analysis tool for detecting depression, beginning with a retrospective feasibility study.
Read More